NightWare, a medical device company focused on treating people with nightmares related to post-traumatic stress disorder (PTSD) and other traumatic events, has announced it has received U.S. Food and Drug Administration (FDA) marketing permission for the NightWareTM therapeutic platform. NightWare is the first and only medical device to be indicated for the temporary reduction of sleep disturbance related to nightmares in adults 22 years or older who suffer from nightmare disorder or have nightmares from PTSD.1
Clinically significant nightmares are a frequent manifestation of PTSD and sexual trauma, and studies show approximately 80% of PTSD patients experience frequent recurrent traumatic nightmares that can persist for months, if not years.2,3,4 These traumatic nightmares and nightmare disorder are an under diagnosed and undertreated condition that is associated with significantly higher rates of suicide.5
"Disruptive and persistent traumatic nightmares associated with post-traumatic stress are significantly underreported and undertreated, and there are no consistently effective treatment options," said General Peter W. Chiarelli, U.S. Army (Retired) and advisor to NightWare. "A device such as the NightWare therapeutic platform that performs the necessary reconnaissance of the mind to identify and interrupt post-traumatic stress-associated nightmares represents a transformational step forward in how we can begin to better support our veterans and active service members suffering from this disabling condition."
The NightWare therapeutic platform utilizes patented artificial intelligence software installed on an Apple Watch that monitors the biometric pattern of an individual's sleep cycle to identify elevated heart rate and body movement associated with nightmares and is then able to interrupt the nightmare by arousing the patient out of the distress state via gentle vibration, prior to the nightmare reaching a severity that would awaken the individual. This feedback decreases nightmare frequency and intensity for patients and, in clinical study, NightWare was well- tolerated and sleep quality was shown to improve.1
"NightWare was founded and built to support veterans and active duty service members who have so unselfishly given of themselves to preserve our freedoms, and suffer emotional, physical and mental distress as a consequence of nightmares," said Grady Hannah, chief executive officer, NightWare. "Helping our current and past military members and all people with this condition is our mission, and we are excited to introduce the NightWare therapeutic platform as the first and only device indicated as an important treatment to reduce sleep disturbances associated with clinically significant nightmares."
The NightWare therapeutic platform was granted Breakthrough Therapy Designation by the FDA in May 2019, in recognition of its preliminary clinical evidence for the treatment of a serious condition for which there is a critical unmet need and demonstration of substantial improvement over available therapy on clinically significant endpoints.
The NightWare therapeutic platform was studied in a 30-day randomized, sham-controlled trial of 70 patients. A sham therapy is an inactive treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial. Patients in the sham group wore the device, but no vibratory stimulation was provided. Safety was assessed using validated measurements of suicidality and sleepiness, and there were no changes in either over the course of the study in either group. Sleep was assessed with two versions of the Pittsburgh Sleep Quality Index scale, the self-rated questionnaire for assessing sleep quality, including a version of that scale that is intended for patients with PTSD. Both the sham and active groups showed improvement on the sleep scales, with the active group showing greater improvement than sham. The evidence demonstrated the probable benefits outweighed the probable risks.1 A large multi-site, randomized sham-controlled trial remains ongoing with a planned enrollment of 240 patients and is expected to be completed in H2 2021.
The NightWare therapeutic platform is available by prescription only and is intended for home use. The NightWare therapeutic platform is not a standalone therapy for PTSD. The NightWare therapeutic platform should be used in conjunction with prescribed medications for PTSD and other recommended therapies for PTSD-associated nightmares and nightmare disorder, according to relevant consensus guidelines. For additional patient and healthcare provider-specific information, please reference the instructions for use available at NightWare.com.
Founded in 2017, NightWare is a privately held, commercial-stage medical device company whose mission is to help people with traumatic nightmares get a more restful night's sleep. The NightWareTM therapeutic platform is the first and only medical device to be indicated for the temporary reduction of sleep disturbance related to nightmares in adults 22 years or older who suffer from nightmare disorder or have nightmares from PTSD. For more information on the company and its platform, visit NightWare.com.
For the Second Consecutive Year, the PTSD Sleep Disturbances Digital Therapeutics Technology is #3 on The Observer list of Top Firms
MINNEAPOLIS, Minn., Jan. 13, 2020 /PRNewswire/ -- NightWare, a privately-held company developing a digital therapeutic treatment for Post Traumatic Stress Disorder (PTSD) sleep disturbances and Nightmare Disorder, has been named by The Observer as one of the nation's hottest medical technology companies. The list, released today, highlights an array of digital health and medical technology startups that are revolutionizing their respective fields. The list was published at the kick-off of the prestigious 38th Annual J.P. Morgan Healthcare Investment Conference #JPM20 in San Francisco, where venture capitalists and health industry experts surveyed by The Observer believe NightWare will be among the most in-demand companies in attendance.
The Observer article describing NightWare's repeat win notes forward momentum in 2019 included the following:
"Over the past 12 months, NightWare received official "Breakthrough Status" designation by the FDA, which is only given to treatments that, according to the FDA, "demonstrate substantial improvement on a clinically significant endpoint over available therapies." In plain English, NightWare might very well become the first prescribable digital therapeutic for a key symptom of PTSD."
"It's an honor to be recognized again by a national publication as one of the most exciting companies in health technology," said Grady Hannah, the CEO of NightWare. "We believe NightWare offers a truly revolutionary way to treat PTSD sleep disturbances and Nightmare Disorder for veterans and those seeking improvement in sleep disorders."
A digital therapeutic is an opportunity for those seeking sleep improvements, including those who prefer to avoid the potential side effects of traditional sleep pharmaceuticals. Hannah noted "Our mission is building a digital therapeutic sleep digital technology that uses biometric sensing to deliver personalized treatment for PTSD sleep disturbances and Nightmare Disorder. Our digital sleep therapeutic technology is unique in that it uses feedback from an individual's own sleep patterns and artificial intelligence (AI) to help alleviate symptoms."
The Observer ranks NightWare #3 in its list of the 20 Hottest Health Start-Ups in 'Flyover Tech' at the 37th Annual J.P. Morgan Healthcare Conference. For details, please see our media advisoryhttps://observer.com/2019/01/flyover-tech-jp-morgan...
MPR's Chris Farrell hosted this Conversation on the Creative Economy at the MANOVA Summit, a global gathering at the Minneapolis Convention Center on the future of health and health care.https://www.mprnews.org/story/2018/10/16/entrepreneurs...